Venus Remedies Limited — Important, 17-04-2025: Updates

Venus Remedies Limited has secured Qualified Infectious Disease Product (QIDP) designation from the US FDA for its investigational product, VRP-034, a novel polymyxin B formulation. This designation highlights VRP-034’s potential to significantly reduce nephrotoxicity—by up to 70% compared to conventional polymyxin B—making it a valuable treatment option for bloodstream infections caused by resistant pathogens.

Developed using the company’s proprietary Renal Guard technology and advanced kidney-on-a-chip models, VRP-034 aims to mitigate the side effects typically associated with polymyxin B therapies. The QIDP status grants various regulatory benefits, including priority review and a possible two-year extension of market exclusivity upon eventual approval.

CEO Saranah Chatterjee emphasized that this milestone reflects Venus Remedies' commitment to addressing the urgent global need for safer polymyxin-based therapies in the fight against antimicrobial resistance. Investors should note this development as a significant advancement in the company’s strategic focus on innovative solutions for serious infections.